Sun Pharma, India’s largest drug maker, said its step-down US subsidiary Taro Pharmaceuticals has acquired companies of Galderma in the US, Japan and Canada.
Galderma specialises in skin related disorders.
Taro has paid around $99.3 million after taking into account working capital adjustments.
“Taro Pharmaceuticals USA, one of the wholly owned subsidiaries of our Taro Pharmaceutical Industries, has agreed to acquire all of the outstanding capital stock of Galderma Holdings Inc (incorporated in Delaware); Proactiv YK (incorporated in Japan); The Proactiv Company Corporation (incorporated in Canada); and other assets of The Proactiv Company Sari, used in the business of developing, manufacturing, marketing, selling and distributing products sold under the Proactiv, Restorative Elements and In Defense of Skin brands,” Sun Pharmaceutical said in an exchange filing.
The brands will help Taro to boost its dermatology portfolio in the US.
Shares of Sun Pharma rose 1.84% to 871.25 on BSE at 2.45 pm on Wednesday, the benchmark Sensex gained 2.47% to 54,700.42 points.
(Catch all the Business News, Breaking News Events and Latest News Updates on The Economic Times.)
Download The Economic Times News App to get Daily Market Updates & Live Business News.